R-EPOCH regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of xxx used to treat Hodgkin's lymphoma. ==Regimen== {{chemo|x|x...") |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}} Rituximab-Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[etoposide]], [[prednisone]], [[vincristine|vincristine (Oncovin)]], [[cyclophosphamide]], and [[doxorubicin|doxorubicin (hydroxydaunorubicin)]] used to treat [[Hodgkin's lymphoma]] and [[HIV]]-associated [[lymphoma]].<ref name="pmid18378569">{{cite journal| author=Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM et al.| title=Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. | journal=J Clin Oncol | year= 2008 | volume= 26 | issue= 16 | pages= 2717-24 | pmid=18378569 | doi=10.1200/JCO.2007.13.1391 | pmc=PMC2409217 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18378569 }} </ref><ref name="pmid20023215">{{cite journal| author=Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF et al.| title=Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. | journal=Blood | year= 2010 | volume= 115 | issue= 15 | pages= 3008-16 | pmid=20023215 | doi=10.1182/blood-2009-08-231613 | pmc=PMC2858478 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20023215 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo| | {{chemo|R|Rituximab}} | ||
{{chemo| | {{chemo|E|Etoposide}} | ||
{{chemo| | {{chemo|P|Prednisone}} | ||
{{chemo| | {{chemo|O|Vincristine (Oncovin)}} | ||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|H|Doxorubicin (Hydroxydaunorubicin)}} | |||
==Indications== | ==Indications== | ||
* [[Hodgkin's lymphoma|Hodgkin's lymphoma, nodular lymphocyte-predominant]] | * [[Hodgkin's lymphoma|Hodgkin's lymphoma, nodular lymphocyte-predominant]]<ref name="pmid18378569">{{cite journal| author=Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM et al.| title=Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. | journal=J Clin Oncol | year= 2008 | volume= 26 | issue= 16 | pages= 2717-24 | pmid=18378569 | doi=10.1200/JCO.2007.13.1391 | pmc=PMC2409217 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18378569 }} </ref> | ||
* [[HIV]]-associated [[lymphoma]]<ref name="pmid20023215">{{cite journal| author=Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF et al.| title=Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. | journal=Blood | year= 2010 | volume= 115 | issue= 15 | pages= 3008-16 | pmid=20023215 | doi=10.1182/blood-2009-08-231613 | pmc=PMC2858478 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20023215 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 18:06, 31 March 2015
|
WikiDoc Resources for R-EPOCH regimen |
|
Articles |
|---|
|
Most recent articles on R-EPOCH regimen Most cited articles on R-EPOCH regimen |
|
Media |
|
Powerpoint slides on R-EPOCH regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-EPOCH regimen at Clinical Trials.gov Trial results on R-EPOCH regimen Clinical Trials on R-EPOCH regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-EPOCH regimen NICE Guidance on R-EPOCH regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-EPOCH regimen Discussion groups on R-EPOCH regimen Patient Handouts on R-EPOCH regimen Directions to Hospitals Treating R-EPOCH regimen Risk calculators and risk factors for R-EPOCH regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-EPOCH regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin regimen
Overview
R-EPOCH regimen refers to a regimen consisting of rituximab, etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and doxorubicin (hydroxydaunorubicin) used to treat Hodgkin's lymphoma and HIV-associated lymphoma.[1][2]
Regimen
RRituximab
EEtoposide
PPrednisone
OVincristine (Oncovin)
CCyclophosphamide
HDoxorubicin (Hydroxydaunorubicin)
Indications
References
- ↑ 1.0 1.1 Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM; et al. (2008). "Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers". J Clin Oncol. 26 (16): 2717–24. doi:10.1200/JCO.2007.13.1391. PMC 2409217. PMID 18378569.
- ↑ 2.0 2.1 Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF; et al. (2010). "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma". Blood. 115 (15): 3008–16. doi:10.1182/blood-2009-08-231613. PMC 2858478. PMID 20023215.